News & Views
Agreement takes Gene Editing to Japanese Pharma
Feb 25 2020
A licensing agreement between Daiichi Sankyo and ERS Genomics provides the Japanese pharmaceutical company with access to foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, for use in its internal research and development to address areas of unmet medical need.
Eric Rhodes, CEO of ERS Genomics, said: “Daiichi Sankyo is our first large pharma licensee in Japan. CRISPR/Cas9 is revolutionary in genome editing; we look forward to observing how the company applies the technology to further advance its R&D operations.”
The Dublin-based company holds an exclusive worldwide license to the foundational intellectual property covering CRISPR/Cas9 for all applications other than use as a human therapeutic.
Digital Edition
LMUK 49.7 Nov 2024
November 2024
News - Research & Events News - News & Views Articles - They’re burning the labs... Spotlight Features - Incubators, Freezers & Cooling Equipment - Pumps, Valves & Liquid Hand...
View all digital editions
Events
Nov 11 2024 Dusseldorf, Germany
Nov 12 2024 Cologne, Germany
Nov 12 2024 Tel Aviv, Israel
Nov 18 2024 Shanghai, China
Nov 20 2024 Karachi, Pakistan